Median progression-free survival and overall survival in patients with newly diagnosed anaplastic oligodendroglioma treated with radiotherapy alone or radiotherapy plus PCV (procarbazine, CCNU, and vincristine) ()

<p><b>Copyright information:</b></p><p>Taken from "Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors"</p><p></p><p>Therapeutics and Clinical Risk Management 2007;3(2):213-224.</p><p>Published online Jan 2007</p><p>PMCID:PMC1936303.</p><p>© 2007 Dove Medical Press Limited. All rights reserved